Recent studies have emphasized the pivotal function of FDX1 across various cancer types, including clear cell renal cell carcinoma (ccRCC), hepatocellular carcinoma (HCC), and gliomas, where its expression levels have been associated with patient survival outcomes (171–173). This evidence concerns the gene FDX1 and hepatocellular carcinoma.